Cardiovascular toxicities associated with immune checkpoint inhibitors

Jiun Ruey Hu, Roberta Florido, Evan Lipson, Jarushka Naidoo, Reza Ardehali, Carlo G. Tocchetti, Alexander R. Lyon, Robert F. Padera, Douglas B. Johnson, Javid Moslehi

Research output: Contribution to journalArticle

Abstract

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year.

Original languageEnglish (US)
Pages (from-to)854-868
Number of pages15
JournalCardiovascular research
Volume115
Issue number5
DOIs
StatePublished - Apr 15 2019

Fingerprint

Programmed Cell Death 1 Receptor
Giant Cell Arteritis
Myositis
Myasthenia Gravis
Myocarditis
Cytotoxic T-Lymphocytes
Vasculitis
Cardiac Arrhythmias
Epidemiology
Heart Failure
Ligands
T-Lymphocytes
Mortality
Antibodies
Neoplasms
Proteins
Therapeutics

Keywords

  • Cardio-oncology
  • Cardiovascular toxicity
  • Immune checkpoint inhibitors
  • Myocarditis
  • Pericarditis
  • Vasculitis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cardiovascular toxicities associated with immune checkpoint inhibitors. / Hu, Jiun Ruey; Florido, Roberta; Lipson, Evan; Naidoo, Jarushka; Ardehali, Reza; Tocchetti, Carlo G.; Lyon, Alexander R.; Padera, Robert F.; Johnson, Douglas B.; Moslehi, Javid.

In: Cardiovascular research, Vol. 115, No. 5, 15.04.2019, p. 854-868.

Research output: Contribution to journalArticle

Hu, JR, Florido, R, Lipson, E, Naidoo, J, Ardehali, R, Tocchetti, CG, Lyon, AR, Padera, RF, Johnson, DB & Moslehi, J 2019, 'Cardiovascular toxicities associated with immune checkpoint inhibitors', Cardiovascular research, vol. 115, no. 5, pp. 854-868. https://doi.org/10.1093/cvr/cvz026
Hu, Jiun Ruey ; Florido, Roberta ; Lipson, Evan ; Naidoo, Jarushka ; Ardehali, Reza ; Tocchetti, Carlo G. ; Lyon, Alexander R. ; Padera, Robert F. ; Johnson, Douglas B. ; Moslehi, Javid. / Cardiovascular toxicities associated with immune checkpoint inhibitors. In: Cardiovascular research. 2019 ; Vol. 115, No. 5. pp. 854-868.
@article{3994615cf4ae4824a9fbad56f8ec2076,
title = "Cardiovascular toxicities associated with immune checkpoint inhibitors",
abstract = "Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year.",
keywords = "Cardio-oncology, Cardiovascular toxicity, Immune checkpoint inhibitors, Myocarditis, Pericarditis, Vasculitis",
author = "Hu, {Jiun Ruey} and Roberta Florido and Evan Lipson and Jarushka Naidoo and Reza Ardehali and Tocchetti, {Carlo G.} and Lyon, {Alexander R.} and Padera, {Robert F.} and Johnson, {Douglas B.} and Javid Moslehi",
year = "2019",
month = "4",
day = "15",
doi = "10.1093/cvr/cvz026",
language = "English (US)",
volume = "115",
pages = "854--868",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Cardiovascular toxicities associated with immune checkpoint inhibitors

AU - Hu, Jiun Ruey

AU - Florido, Roberta

AU - Lipson, Evan

AU - Naidoo, Jarushka

AU - Ardehali, Reza

AU - Tocchetti, Carlo G.

AU - Lyon, Alexander R.

AU - Padera, Robert F.

AU - Johnson, Douglas B.

AU - Moslehi, Javid

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year.

AB - Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year.

KW - Cardio-oncology

KW - Cardiovascular toxicity

KW - Immune checkpoint inhibitors

KW - Myocarditis

KW - Pericarditis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85064513217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064513217&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvz026

DO - 10.1093/cvr/cvz026

M3 - Article

C2 - 30715219

AN - SCOPUS:85064513217

VL - 115

SP - 854

EP - 868

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 5

ER -